Skip to main content
Grafa
Vyome wins China patent for acne gel program
Image for illustrative purposes only. Not a real photo.

Vyome wins China patent for acne gel program

Share
  • Vyome Holdings (NASDAQ:HIND) received a Chinese patent for its besifloxacin topical gel program targeting inflammatory acne.
  • The patent expands formulation and therapeutic use protection, including treatment of antibiotic-resistant acne.
  • Vyome said the intellectual property strengthens its position in China’s estimated $600 million annual acne market by 2035.

Vyome Holdings (NASDAQ:HIND) said the China National Intellectual Property Administration granted a patent covering formulation and therapeutic uses for its besifloxacin topical gel program.

The approval strengthens Vyome’s intellectual property position in dermatology compared with its earlier-stage patent protection focused primarily on broader compound claims.

The patent includes claims for treating inflammatory acne, acne-related inflammation, and antibiotic-resistant Propionibacterium acnes infections.

Vyome said the expanded protection improves its positioning in China’s dermatology market, which it estimates could reach about $600 million annually by 2035.

The company said its lead clinical priority remains VT-1953 for malignant fungating wounds, while the acne program is being developed as a secondary asset.

Vyome said the stronger intellectual property estate may support future licensing or partnering opportunities without requiring significant additional investment.

The company added that formulation-level innovation is a key component of its broader strategy to build value across its immuno-inflammatory pipeline.